Society of Family Planning interim clinical recommendations: Self-managed abortion

The Society of Family Planning has released an interim clinical recommendation for self-managed abortion. Increased interest and attention directed towards those self-managing their own care aims to demedicalize the abortion process and support those who are making this decision, regardless of their circumstances. This interim recommendation is intended to serve as a guide to aid clinical practice in an anticipated post-Roe landscape, and is based on the evidence available at the time of publication and on expert opinion. Please share this document with your networks.

Through the Honoring community-based organizations as knowledge generators funding opportunity, the Society will support and elevate the knowledge of individuals [...] READ MORE
We are delighted to announce the 2023 SFP NIH Navigation Cohort, an NIH proposal development program led by Vanessa Dalton, [...] READ MORE
In an effort to support and elevate the knowledge of individuals working at community-based organizations, with a focus on lifting [...] READ MORE
Join us in listening in on our new podcast series, Source for Science. Our first episode, Clinician perspectives on self-managed abortion features Nisha Verma, [...] READ MORE
The Society of Family Planning Research Fund is seeking participants to join a time-limited learning community for researchers focused on [...] READ MORE
The Society of Family Planning Research Fund is committed to supporting an inclusive, multidisciplinary, skilled, and well-connected community of scholars [...] READ MORE
In an effort to document the impact of changes to the US legal abortion landscape on people whose access to [...] READ MORE
We are excited to share that 28 Society of Family Planning members are listed as key authors on our fifth-annual [...] READ MORE
Together, we have faced unprecedented challenges this year. And we, at the Society of Family Planning, have never been more [...] READ MORE
Today, we have learned that the US Food and Drug Administration’s review of the risk evaluation and mitigation strategy (REMS) [...] READ MORE